12
Participants
Start Date
March 31, 2004
Primary Completion Date
October 31, 2006
Study Completion Date
January 31, 2020
rAAV2-CB-hAAT Gene Vector
Participants will attend a 5-day inpatient visit, during which they will receive a series of injections consisting of one of four different doses of rAAV2-CB-hAAT.
University of Florida, College of Medicine, Department of Pediatrics, Gainesville
UMass Medical School, Worcester
Collaborators (1)
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Alpha-1 Foundation
OTHER
University of Florida
OTHER
National Center for Research Resources (NCRR)
NIH
University of Massachusetts, Worcester
OTHER